



LISTING OF THE CLAIMS

1. (Currently Amended) A method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula I:



wherein a wavy segments indicate either the \square or \square configuration; the dashed bond represents a double bond or a single bond;

U is $=O$,




wherein W is halogen;

Z is O or S;

Ar is selected from the group consisting of aryl or heteroaryl radicals having from 4 to 10 carbon atoms and substituted derivatives of said aryl and heteroaryl radicals; n is 0 or an integer of from 1 to 4; x and y are 1 or 0, provided that when x is 1, y is 0 and when x is 0, y is 1; R1 is hydrogen or a lower alkyl radical or a substituted lower alkyl radical having up to six carbon atoms; X is selected from the group consisting of $-OR_1$ and $-N(R^1)_2$; Y is $=O$ or represents 2 hydrogen radicals, Z is S or O; wherein the substituent on the lower alkyl, aryl or heteroaryl radical is selected from the group consisting of lower alkyl, hydroxy, lower alkyloxy, halogen, trifluoromethyl (CF_3), COR_1 , $COCF_3$, SO_2NR_1 , SO_2NH_2 , NO_2 and CN and/or the pharmaceutically acceptable salts of said compounds and/or esters.


2. (Original) The method of claim 1 wherein said compound is represented by formula II:



wherein n is 0 or 1, 2, 3 or 4; hatched lines at position C-8 and C-11 indicate the α orientation; and the triangle at position C-12 represents the β orientation.


3. (Original) The method of claim 2 wherein Y is = O and X is -OR¹.
4. (Currently Amended) The method of claim 3 wherein

$$U \text{ is } =\text{O} \text{ or } \text{Cl} \quad \begin{array}{c} \text{---} \\ \diagup \\ \text{---} \end{array} \quad \begin{array}{c} \text{---} \\ \diagdown \\ \text{---} \end{array} \quad \text{H}$$
5. (Original) The method of claim 4 wherein Z is O.
6. (Original) The method of claim 4 wherein R¹ is H or methyl.
7. (Original) The method of claim 4 wherein Ar is phenyl.
8. (Original) The method of claim 4 wherein x is 0.
9. (Original) An ophthalmic solution comprising a therapeutically effective amount of a compound of formula I, as defined in Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle, packaged in a container suitable for metered application.
10. (Currently Amended) The ophthalmic solution of Claim 9 wherein said compound is a compound of Formula III:




11. (Original) A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic solution in said container comprising a compound of formula I as defined in Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle.

12. (Currently Amended) The product of claim 11 wherein said compound is a compound of Formula III:



13. (Currently Amended) The A compound represented by formula I:



wherein a wavy segments indicate either the \square or \square configuration; the dashed bond represents a double bond or a single bond;




wherein W is halogen;

Z is O or S;


Ar is selected from the group consisting of aryl or heteroaryl radicals having from 4 to 10 carbon atoms and substituted derivatives of said aryl and heteroaryl radicals; n is 0 or an integer of from 1 to 4; x and y are 1 or 0, provided that when x is 1, y is 0 and when x is 0, y is 1; R^1 is hydrogen or a lower alkyl radical or a substituted lower alkyl radical having up to six carbon atoms; X is selected from the group consisting of $-\text{OR}^1$ and $-\text{N}(\text{R}^1)_2$; Y is $=\text{O}$ or represents 2 hydrogen radicals; wherein the substituent Z is S or O; wherein the substituent on the lower alkyl, aryl or heteroaryl radical is selected from the group consisting of lower alkyl, hydroxy, lower alkyloxy, halogen, trifluoromethyl (CF_3), COR^1 , COCF_3 , SO_2NR^1 , SO_2NH_2 , NO_2 and CN and/or the pharmaceutically acceptable salts of said compounds and/or esters.

14. (Original) The compound of claim 13 wherein said compound is formula II:



wherein n is 0 or 1, 2, 3 or 4; hatched lines at position C-8 and C-11 indicate the α orientation; and the triangle at position C-12 represents the β orientation.

15. (Original) The compound of claim 14 wherein said compound is represented by formula II:



wherein n is 0 or 1, 2 or 4; hatched lines at position C-8 and C-11 indicate the α orientation; and the triangle at position C-12 represents the β orientation.

16. (Original) The compound of claim 15 wherein Y is = O and X is -OR¹.

17. (Currently Amended) The compound of claim 16 wherein



18. (Original) The compound of claim 17 wherein Z is O.

19. (Original) The compound of claim 18 wherein R¹ is H or methyl.
20. (Original) The compound of claim 19 wherein Ar is phenyl.
21. (Original) The method of claim 1 wherein said compound is selected from the group consisting of

(Z)-7-((1R,2S,3R)-2-Butylcarbamoyloxymethyl-3-hydroxy-5-oxo-cyclopentyl)-hept-5-enoic acid methyl ester

(Z)-7-((1R,2S,3R)-2-Butylcarbamoyloxymethyl-3-hydroxy-5-oxo-cyclopentyl)-hept-5-enoic acid

(Z)-7-((1R,2S,3R,5R)-2-Butylcarbamoyloxymethyl-5-chloro-3-hydroxy-cyclopentyl)-hept-5-enoic acid methyl ester

(Z)-7-((1R,2S,3R,5R)-2-Butylcarbamoyloxymethyl-5-chloro-3-hydroxy-cyclopentyl)-hept-5-enoic acid

(Z)-7-((1R,2S,3R)-3-Hydroxy-5-oxo-2-phenethylcarbamoyloxymethyl-cyclopentyl)-hept-5-enoic acid methyl ester

(Z)-7-((1R,2S,3R)-3-Hydroxy-5-oxo-2-phenethylcarbamoyloxymethyl-cyclopentyl)-hept-5-enoic acid

(Z)-7-((1R,2S,3R)-2-Butylthiocarbamoyloxymethyl-3-hydroxy-5-oxo-cyclopentyl)-hept-5-enoic acid methyl ester

(Z)-7-((1R,2S,3R)-2-Butylthiocarbamoyloxymethyl-3-hydroxy-5-oxo-cyclopentyl)-hept-5-enoic acid.

22. The compound of claim 13 wherein said compound is selected from the group consisting of (Z)-7-((1R,2S,3R)-2-Butylcarbamoyloxymethyl-3-hydroxy-5-oxo-cyclopentyl)-hept-5-enoic acid methyl ester

(Z)-7-((1R,2S,3R)-2-Butylcarbamoyloxymethyl-3-hydroxy-5-oxo-cyclopentyl)-hept-5-enoic acid

(Z)-7-((1R,2S,3R,5R)-2-Butylcarbamoyloxymethyl-5-chloro-3-hydroxy-cyclopentyl)-hept-5-enoic acid methyl ester

(Z)-7-((1R,2S,3R,5R)-2-Butylcarbamoyloxymethyl-5-chloro-3-hydroxy-cyclopentyl)-hept-5-enoic acid

(Z)-7-((1R,2S,3R)-3-Hydroxy-5-oxo-2-phenethylcarbamoyloxymethyl-cyclopentyl)-hept-5-enoic acid methyl ester

(Z)-7-((1R,2S,3R)-3-Hydroxy-5-oxo-2-phenethylcarbamoyloxymethyl-cyclopentyl)-hept-5-enoic acid

(Z)-7-((1R,2S,3R)-2-Butylthiocarbamoyloxymethyl-3-hydroxy-5-oxo-cyclopentyl)-hept-5-enoic acid methyl ester

(Z)-7-((1R,2S,3R)-2-Butylthiocarbamoyloxymethyl-3-hydroxy-5-oxo-cyclopentyl)-hept-5-enoic acid.